Bill > S778

This bill directs the Health Policy Commission to conduct a study examining the feasibility of establishing a program for the Commonwealth to direct the manufacture of generic or biosimilar prescription drugs. The study will analyze whether such a program would increase competition, lower prices, address shortages, reduce costs for public and private purchasers, taxpayers, and consumers, and increase patient access to affordable drugs. The study will examine factors that contribute to drug costs in the Commonwealth, how generic prescription drug costs affect MassHealth spending and healthcare costs, and whether a state-directed prescription drug manufacturing program would be reasonable and effective at reducing drug prices and healthcare costs in Massachusetts. The Commission will submit a report of its findings and recommendations, including a cost-benefit analysis and a plan for establishing such a program if deemed effective.

Health and Social Services

https://malegislature.gov/Bills/193/S778